Shanghai Fosun Pharmaceutical (SHA:600196) secured approval from China's drug administrator to conduct phase Ib/II clinical trials of HLX43 for injection.
The drug will be used to treat advanced or metastatic solid tumors, according to a Wednesday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments